Krystal Biotech revenues top $116M as gene therapy adoption accelerates

Krystal Biotech (NASDAQ:KRYS) reported robust financial results for the first quarter of 2026, highlighted by continued commercial momentum for VYJUVEK, the first and only redosable gene therapy for dystrophic epidermolysis bullosa.

The company recorded $116.4 million in global net product revenue for the quarter, reflecting steady market penetration for the therapy.

The company concluded the quarter with a formidable balance sheet, reporting $1 billion in cash, cash equivalents, and investments.

This liquidity provides Krystal with a significant runway to fund its diverse clinical pipeline and commercial expansion efforts.

Looking ahead to the full fiscal year, management provided non-GAAP guidance for combined research and development (R&D) and selling, general, and administrative (SG&A) expenses in the range of $175 million to $195 million.

Beyond its commercial success, Krystal achieved several clinical milestones during the quarter.

In its ophthalmology program, the company announced that enrollment is now complete for the Phase 2 IOLITE trial of KB803, with 16 patients randomized.

Top-line results from this study are anticipated in the fourth quarter of 2026.

Additionally, enrollment remains ongoing for the KB801 program, which expects to reach its full cohort of 60 patients and release data by year-end.

The company also received a significant regulatory boost from the U.S. Food and Drug Administration.

The FDA granted "Platform Technology Designation" to the engineered viral vectors used in KB407 and KB111.

This designation is designed to streamline the development and review process for subsequent products using the same underlying technology, potentially accelerating the company's time-to-market for future respiratory and skin-related therapies.